Search Results - Jorge Romaguera

Refine Results
  1. 1
    Experience with obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma

    Experience with obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma by Yasuhiro Oki, Amanda Copeland, Fredrick B. Hagemeister, Luis Fayad, Michelle A. Fanale, Jorge Romaguera, Anas Younes

    Published 2012
    Get full text
    Carta
    Save to List
    Saved in:
  2. 2
    Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma

    Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma by Victor Yazbeck, Daniela Buglio, Georgios Georgakis, Li Yang, Eiji Iwado, Jorge Romaguera, Seiji Kondo, Anas Younes

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Original article: A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the ‘tumor score’

    Original article: A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the ‘tumor score’ by José Rodríguez, Fernando Cabanillas, Peter McLaughlin, F Swan, Maria Alma Rodriguez, Frederick Hagemeister, Jorge Romaguera

    Published 1992
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells

    Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells by Liang Zhang, Jing Yang, Jianfei Qian, Haiyan Li, Jorge Romaguera, Larry W. Kwak, Michael Wang, Qing Yi

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Primary hepatic lymphoma

    Primary hepatic lymphoma by Ray D. Page, Jorge Romaguera, Barbara M. Osborne, L. Jeffrey Medeiros, José Rodríguez, L North, César Sanz-Rodrı́guez, Fernando Cabanillas

    Published 2001
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature

    Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature by Andres O. Soriano, Michael A. Thompson, Joan H. Admirand, Luis Fayad, Alma María Rodríguez, Jorge Romaguera, Fredrick B. Hagemeister, Barbara Pro

    Published 2007
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes

    Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes by Chan Y. Cheah, Dai Chihara, Jorge Romaguera, Nathan Fowler, John F. Seymour, Fredrick B. Hagemeister, Richard E. Champlin, M.L. Wang

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

    Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma by Yasuhiro Oki, Barbara Pro, Luis Fayad, Jorge Romaguera, Felipe Samaniego, Fredrick Hagemeister, Sattva S. Neelapu, Peter McLaughlin, André Goy, Anas Younes

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

    Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma by Yasuhiro Oki, Michelle A. Fanale, Jorge Romaguera, Luis Fayad, Nathan Fowler, Amanda Copeland, Felipe Samaniego, Larry W. Kwak, Sattva S. Neelapu, Michael Wang, Lei Feng, Anas Younes

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha

    Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha by Peter McLaughlin, Elihu H. Estey, Armand B. Glassman, Jorge Romaguera, Felipe Samaniego, Ana Ayala, Kimberly Hayes, Anne Marie Maddox, H. Alejandro Preti, Fredrick B. Hagemeister

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

    A pilot study of rituximab in patients with recurrent, classic Hodgkin disease by Anas Younes, Jorge Romaguera, Frederick Hagemeister, Peter McLaughlin, Maria Alma Rodriguez, Paolo Fiumara, André Goy, Sima Jeha, John T. Manning, Dan Jones, Lynne V. Abruzzo, L. Jeffrey Medeiros

    Published 2003
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma

    Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma by Bita Esmaeli, Peter McLaughlin, Barbara Pro, Felipe Samaniego, Isis Gayed, Fredrick B. Hagemeister, Jorge Romaguera, Fernando Cabanillas, Sattva S. Neelapu, R. Banay, Luis Fayad, M. Wayne Saville, Larry W. Kwak

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    The Clinical Significance of Molecular Response in Indolent Follicular Lymphomas

    The Clinical Significance of Molecular Response in Indolent Follicular Lymphomas by Armando López‐Guillermo, Fernando Cabanillas, Peter McLaughlin, Terry Smith, Fredrick B. Hagemeister, M. A. Rodriguez, Jorge Romaguera, Anas Younes, Andreas H. Sarris, H. Alejandro Preti, William Pugh, Ming-Seng Lee

    Published 1998
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma

    Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma by Barbara Pro, Brian Leber, Mitchell R. Smith, Luis Fayad, Jorge Romaguera, Fredrick B. Hagemeister, Maria Alma Rodriguez, Peter McLaughlin, Felipe Samaniego, James A. Zwiebel, Adriana López, Larry W. Kwak, Anas Younes

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma

    Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma by Michael Wang, Yasuhiro Oki, Barbara Pro, Jorge Romaguera, Maria Alma Rodriguez, Felipe Samaniego, Peter McLaughlin, Frederick Hagemeister, Sattva S. Neelapu, Amanda Copeland, Barry I. Samuels, Evelyne M. Loyer, Yuan Ji, Anas Younes

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial

    Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial by A H Sarris, Frederick Hagemeister, Jorge Romaguera, Maritza Rodríguez, Peter McLaughlin, Apostolia M. Tsimberidou, L. Jeffrey Medeiros, Barry I. Samuels, O. Pate, M. Oholendt, Hagop M. Kantarjian, C. Burge, Fernando Cabanillas

    Published 2000
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Four‐year follow‐up of a single arm, phase <scp>II</scp> clinical trial of ibrutinib with rituximab (<scp>IR</scp>) in patients with relapsed/refractory mantle cell lymphoma (<scp>MCL</scp>)

    Four‐year follow‐up of a single arm, phase <scp>II</scp> clinical trial of ibrutinib with rituximab (<scp>IR</scp>) in patients with relapsed/refractory mantle cell lymphoma (<scp>... by Preetesh Jain, Jorge Romaguera, Samer A. Srour, Hun Ju Lee, Frederick Hagemeister, Jason R. Westin, Luis Fayad, Felipe Samaniego, Maria Badillo, Liang Zhang, L. Nastoupil, Rashmi Kanagal‐Shamanna, Nathan Fowler, Michael Wang

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Phase II trial of denileukin diftitox for relapsed/refractory T‐cell non‐Hodgkin lymphoma

    Phase II trial of denileukin diftitox for relapsed/refractory T‐cell non‐Hodgkin lymphoma by Nam H. Dang, Barbara Pro, Fredrick B. Hagemeister, Felipe Samaniego, Dan Jones, Barry I. Samuels, Maria Alma Rodriguez, André Goy, Jorge Romaguera, Peter McLaughlin, Ann T. Tong, Francesco Turturro, Pamela L. Walker, Luis Fayad

    Published 2006
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy

    Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy by Issa F. Khouri, M.-S. Lee, Jorge Romaguera, Nadeem Q. Mirza, Hagop M. Kantarjian, M Körbling, Maher Albitar, Sergio Giralt, Brian L. Samuels, Paolo Anderlini, José Rodríguez, B von Wolff, James Gajewski, Fernando Cabanillas, R. Champlin

    Published 1999
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma

    Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-C... by Anas Younes, Stella Kim, Jorge Romaguera, Amanda Copeland, Silvana de Castro Farial, Larry W. Kwak, Luis Fayad, Frederick Hagemeister, Michelle A. Fanale, Sattva S. Neelapu, John M. Lambert, Rodica Morariu-Zamfir, Sandrine Payrard, Leo I. Gordon

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: